Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally...

Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...